Rho Webinar Shares Tips on Understanding New Drug Applications
Published: Aug 06, 2018
WHAT: Rho, a full-service contract research organization (CRO), is offering a webinar highlighting tips on how to understand what is involved in a New Drug Application (NDA). The webinar will cover regulatory strategy, data integration and readiness, and electronic publishing, as well as tips that can help you avoid common pitfalls in the submissions process.
Marketing application submissions, including NDAs, biologics license applications (BLAs), and premarket approvals (PMAs) in the US, are the culmination of years of research and the final hurdle before a product makes it to market. During this webinar, experts David Shoemaker, Ph. D, senior vice president, research and development and Rob Woolson, J.D., M.S., chief strategist, biostatistics and data standards for regulatory submissions at Rho will help you navigate submissions in the most efficient and effective way.
WHO: David Shoemaker, Ph. D, senior vice president, research and development, Rho
Rob Woolson, J.D., M.S., chief strategist, biostatistics and data standards for regulatory submissions, Rho
WHEN: Tuesday, August 14, 2018
1 p.m. ET/ 10 a.m. PT
Duration: one hour
Click here to register for the free webinar.
DETAILS: For media inquiries, please contact Jordan Lockhart at Largemouth Communications, (919) 459-6461, email@example.com.
ABOUT: Rho, a privately-held, contract research organization (CRO) located in Chapel Hill, NC, provides a full range of clinical research services across the entire drug development process. For 34 years, Rho has been a trusted partner to some of the industry’s leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience. For more information, please visit www.rhoworld.com and follow us on Twitter.